Clinical Review on the Management of Metastatic Renal Cell Carcinoma. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Tran, Jennifer; Ornstein, Moshe C.
• Is Part Of: JCO oncology practice. Volume 18:Issue 3(2022)
• Publication Date: 2022-03
• Subjects: Oncology -- Periodicals; Medical Oncology; Neoplasms; Oncology; Periodicals; 616.994
• DOI: 10.1200/OP.21.00419
• Languages: English
• ISSNs: 2688-1527

Abstract

Abstract : Renal cell carcinomas vary considerably in their tumor biology and disease course, which is reflected in the range of treatment paradigms in localized and metastatic renal cell carcinoma (mRCC). Active surveillance remains an important component of all renal cell carcinoma management. In mRCC, the rapid evolution from cytokine-based therapy to targeted therapy to immunotherapy with checkpoint blockade has revolutionized the field and drastically altered treatment outcomes. More recently, combination therapies have become a standard of care for most patients with mRCC. In this review, we highlight recent critical data that led to changes in treatment paradigms and provide a practical framework for the management of patients with mRCC.